ASH 2014: Phase Ib dose escalation trial of SAR650984 (anti-CD38 monoclonal antibody) in combination with lenalidomide and dexamethasone improves overall response rate and clinical benefit response in relapsed or refractory myeloma - 101271

Spotlight
Video

ASH 2014: Phase Ib dose escalation trial of SAR650984 (anti-CD38 monoclonal antibody) in combination with lenalidomide and dexamethasone improves overall response rate and clinical benefit response in relapsed or refractory myeloma

EMJ has 458 videos Subscribe Here

Loading........
Description: At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Thomas Martin (University of California San Francisco, San Francisco, CA) discusses a phase Ib dose escalation trial of SAR650984 (anti-CD38 monoclonal antibody) in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Shared By : EMJ
Posted on : 12/09/14
Added : 3 years ago
Category : Multiple Myeloma



Recommended

Nothing found.

More From EMJ

Nothing found.